Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality

NCT02889133
View directory record Official record
Conditions
Iron Deficiency
Interventions
Iron-dextran, Saline, Blood Donation, 24-hour PTR
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Not applicable Interventional

A Trial of Restrictive Versus Traditional Blood Transfusion Practices in Burn Patients

NCT01079247
View directory record Official record
Conditions
Burn Injury
Interventions
Restrictive transfusion threshold, Liberal transfusion threshold
Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years to 90 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Colton, California • Fresno, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 21, 2026, 5:45 PM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

NCT02633943
View directory record Official record
Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2035
U.S. locations
6
States / cities
Oakland, California • Chicago, Illinois • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 21, 2026, 5:45 PM EDT
Not listed No phase listed Observational

Massive Transfusion in Trauma Patient Registry

NCT06136715
View directory record Official record
Conditions
Trauma
Interventions
blood products as a part of Massive Transfusion Protocol
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 21, 2026, 5:45 PM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 5:45 PM EDT
Completed No phase listed Observational

Curative Versus Disease-Modifying Therapies in Children With Severe Sickle Cell Disease

NCT01369160
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Quality of Life measures
Behavioral
Lead sponsor
Emory University
Other
Eligibility
3 Years to 23 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utilizing A Single Session Problem-Solving Intervention With Caregivers of Pediatric Patients Receiving Chronic Transfusion to Treat Sickle Cell Disease

NCT04606160
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Single Session Problem-Solving Intervention
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 21, 2026, 5:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

NCT05568225
View directory record Official record
Conditions
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Interventions
Etavopivat
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Miami, Florida • Ocala, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 5:45 PM EDT
Withdrawn No phase listed Observational

Detailed Evaluation of Microchimerism

NCT01094197
View directory record Official record
Conditions
Chimerism, Blood Transfusion, Wounds and Injuries, Hematopoiesis
Interventions
Not listed
Lead sponsor
Vitalant Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 21, 2026, 5:45 PM EDT
Terminated No phase listed Observational

Predicting Lung Injury From Transfusion in Patients With Liver Disease

NCT01756690
View directory record Official record
Conditions
Transfusion-related Acute Lung Injury, Chronic Liver Disease, Gastrointestinal Bleeding
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 21, 2026, 5:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neonatal Platelet Transfusion Threshold Trial

NCT06676904
View directory record Official record
Conditions
Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
Interventions
Higher Platelet Transfusion Threshold, Lower Platelet Transfusion Threshold
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
1 Hour to 48 Hours
Enrollment
2,433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 21, 2026, 5:45 PM EDT
Terminated Early Phase 1 Interventional

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

NCT05841706
View directory record Official record
Conditions
Resectable Pancreatic Carcinoma
Interventions
Arm I Packed Red Blood Cell Transfusion (Hgb < 7 g/dL), Arm II Packed Red Blood Cell Transfusion (Hgb < 9 g/dL), Computed Tomography, X-Ray Imaging, Biospecimen Collection, Survey Administration, Pancreatectomy
Biological · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Olaratumab in Soft Tissue Sarcoma

NCT01185964
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Olaratumab, doxorubicin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 21, 2026, 5:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating People With Thalassemia: The Thalassemia Longitudinal Cohort (TLC) Study

NCT00661804
View directory record Official record
Conditions
Thalassemia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
5 Years and older
Enrollment
416 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Phase 3 Interventional

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

NCT04935177
View directory record Official record
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list
Drug · Procedure · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Microparticles in Stored RBC as Potential Mediators of Transfusion Complications

NCT01185600
View directory record Official record
Conditions
Coronary Artery Bypass
Interventions
Washed RBC, Unwashed RBC
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 5:45 PM EDT
Withdrawn Phase 1 Interventional

Three Dosing Schedules of Oral Rigosertib in MDS Patients

NCT02075034
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

NCT02158858
View directory record Official record
Conditions
Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS), Preleukemia, Primary Myelofibrosis, Myeloproliferative Disorders, Bone Marrow Disease, Hematological Disease, Precancerous Conditions, Neoplasms, Leukemia, Neoplasms by Histologic Type, Essential Thrombocytosis
Interventions
Pelabresib, Ruxolitinib
Drug
Lead sponsor
Constellation Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Phase 1 Interventional

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

NCT01683955
View directory record Official record
Conditions
Acute Blood Loss Anemia, Osteoarthritis, Hip
Interventions
Tranexamic acid, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 21, 2026, 5:45 PM EDT
Not listed Phase 1Phase 2 Interventional

Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs

NCT00319657
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total lymphoid irradiation
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Permeability Factor in Focal Segmental Glomerulosclerosis

NCT00007475
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Plasma exchange, Cyclophosphamide
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 21, 2026, 5:45 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 5:45 PM EDT
Active, not recruiting Not applicable Interventional

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

NCT04922307
View directory record Official record
Conditions
Kidney Cancer
Interventions
Blood Sparing Protocol, Standard Blood Replacement
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 5:45 PM EDT
Completed Not applicable Interventional Results available

Study of the Effect of Differing Platelet Transfusion Times in Neonates

NCT00948792
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Short platelet transfusion, Long platelet transfusion
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 21, 2026, 5:45 PM EDT